LGC Expands into Clinical Quality Control Tools with SeraCare Acquisition

LGC said today it has acquired SeraCare Life Sciences for an undisclosed price, in a deal that will expand the buyer into providing clinical quality control tools for global in vitro diagnostics manufacturers and clinical laboratories.

SeraCare provides quality control materials for infectious disease testing through its ACCURUN reagents, as well as through its Seraseq products for the clinical next-generation sequencing (NGS) market, focusing on oncology, non-invasive prenatal testing (NIPT) and inherited disease testing.

Click to see full article